Patients with recurrent intermediate-stage hepatocellular carcinoma and microvascular invasion–positive status benefit from longer survival times by using a combined treatment of sorafenib with tra... BackgroundThe evidence of combining sorafenib with transarterial chemoembolization (TACE) for intermediate-stage recurrent hepatocellular carcinoma (HCC) is limited. Patient responses to this treat...